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molecule of the protein probably binds seven copper ions in a
protein of molecular weight 132000, giving 0-33% of metal in the
protein. In other words the serum caeruloplasmin found in the
neonates should bind 300 pg copper and in the patients with
Wilson’s disease 330 pg. These figues closely approximate to the
5 - 0 mol/1 (315 g/1) shown in the figure. In other words there is no
"free copper" present in either of the two groups shown in this
series, albeit the numbers are small. This might seem surprising for
patients with Wilson’s disease, though they may have received long
term treatment with penicillamine and have been effectively
"decoppered"-but this explanation would seem to be improbable
for the neonates.
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RIFAMPICIN AND ANTIBIOTIC-ASSOCIATED
COLITIS
SIR,-We were interested in the case-reports of rifampicin
(rifampin) associated pseudomembranous colitis published in The
Lancet of Nov. 29.1,2 We tested 20 isolates of Clostridium difficile
and found all to be very susceptible to rifampicin, with minimum
inhibitory concentrations (MIC) <0-2 2 /-lg/ml. We then did.
experiments to see if rifampicin would induce colitis in the Golden
Syrian hamster, an animal in which antibiotic-associated colitis
(AAC) is readily induced by many antimicrobial agents. When
hamsters were given single doses of rifampicin, orogastrically or
subcutaneously, none acquired enterocolitis. Next, to see if
rifampicin could prevent AAC caused by other antibiotics, it was
given subcutaneously to hamsters before they were given
subcutaneous clindamycin. In these hamsters colitis sometimes
developed, but they lived longer than those receiving clindamycin
alone. C. difficile isolates from hamsters with enterocolitis were very
susceptible to rifampicin.
After six months of experiments with rifampicin in these quarters,
large numbers of animals died unexpectedly with caecitis after
receiving rifampicin only. C. difficile isolates from the caecal
contents of these animals were resistant to rifampin (MIC >100
pg/ml).
Thus, rifampicin at first protected against AAC and the C. difficile
isolates were susceptible to it. However, typical clinical and
morphological changes compatible with AAC were induced with
rifampicin after the organisms had acquired resistance to rifampicin
following frequent exposure of the hamster colony to the drug.
Development of rifampicin resistance in C. difficile might be most
likely to happen in people on long-term rifampicin (e.g., for
tuberculosis). Thus, it would not be surprising if rifampicin were to
be implicated as a cause of AAC in man. Our experiments also
indicate the importance of cross-infection with C. difficile in animal
quarters.
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SIR,-Letters from the chairmen of the Child Health Computing
Committee (Jan. 3, p. 47) and of the Central Ethical Committee of
the B.M.A. (Feb. 7, p. 327), and a Lancet editorial (Dec. 6) on
computerised child health records, claim that there is a shortage of
facts for debate and that facts are hard to come by. This is not so.
The report of Ontario’s Royal Commission on the Confidentiality
of Health Records3 runs to three volumes, summarising three years’
investigation by an Ontario Supreme Court judge. It catalogues
1 Melanger M, et al. Pseudomembranous colitis and rifampin. Lancet 1980; ii: 1192,
2. Bommelaer G, et al Pseudomembranous colitis and rifampin. Lancet 1980; ii: 1192.
3 Report of the Commission of Inquiry into the Confidentiality of Health Records
(chairman Justice Horace Krever). Government of Province of Ontario, Canada,
1980.
widespread, frequent, routine, illegal abuse of medical records by
the national security service (on one occasion for political
blackmail), by the local police, by private detectives, by insurance
companies, and by immigration authorities in the province of
Ontario. For example, the Immigration Department made 60-70
requests monthly for information from health records and Ministry
of Health officials withheld that fact from the provincial Minister of
Health (the supposed representative of the people). With the
frequently changing immigration laws in the U.K., it is not difficult
to see that the U.K. immigration authorities would similarly have
great recourse to information from computerised health records.
With regard to child health Justice Krever comments that existing
laws aimed at health care workers do not "provide adequate assur-
ance that the confidentiality of school children’s health records will
be protected".
Justice Krever made 170 recommendations for changes to
(Ontario) law and, with medical computer specialist advice, made
copious recommendations to promote privacy and security of
computer records.
I, for one, find. 1662 pages of evidence and closely reasoned
argument sufficient facts for the current debate.
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CYCLOPHOSPHAMIDE AND SUPPRESSOR CELL
FUNCTION
SIR,-Dr Raube and colleagues (Jan. 31, p. 235) describe long-
term impairment of suppressor cell function in patients who were
treated with cyclosphosphamide because of minimal change
nephropathy. For several reasons their results are debatable.
Their assay for T suppressor cell function was unusual.
Responder cells were pre-incubated for 24 h at 37&deg;C before
suppressor cells were added, which in itself influences suppressor
cell function, since short-living suppressor cells might be lost
during pre-incubation. Their assay is further obscured by their not
removing concanavalin A from the activated suppressor cells by
treatment with a-methylglucoside2 and not separating concanavalin
A activated T cells from monocytes, since monocytes also may
function as suppresor cells in this system.3 The doubled cell density
in the reconstituted culture of suppressor and responder cells
compared with the cell densities in the separate cultures of these
cells, might by itself be responsible for the observed "suppression".
Although Raube et al. noted differences between several groups of
patients, I am not at all convinced that they have detected
impairment of suppressor-cell function.
These workers do not give their criteria for treating some patients
with cyclophosphamide. Obviously, patients who have not
responded to corticosteroids differ from the remainder before
cyclophosphamide treatment begins. Since suppressor-cell function
was not measured before treatment, altered lymphocyte reactivity
several years after the last dose cannot be attributed to
cyclophosphamide.
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COAGULASE-NEGATIVE STAPHYLOCOCCI
SIR,-Your Jan. 17 editorial well summarises the importance of
the opportunistic pathogen Staphylococcus epidermidis, although you
under-rate the importance of Staph. saprophyticus (Micrococcus sp).
However, on the choice of antibiotic treatment for Staph. epidermidis
infections you are too gloomy. You record the conclusion ofForse et
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